

Date – November 27, 2025

To, BSE Limited (“BSE”), Corporate Relationship Department, 2 nd Floor, New Trading Ring, P.J. Towers, Dalal Street, Mumbai – 400001	To, National Stock Exchange of India Limited (“NSE”) “Exchange Plaza”, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai – 400051
BSE Scrip code: 543399	NSE Symbol: TARSONS

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Further Investment in Tarsons Life Science Pte. Ltd., a Wholly-Owned Subsidiary of the Company in Singapore, to repay loans and other operational & financial obligations.

Dear Sir/Madam,

With reference to the captioned subject and pursuant to the provisions of Regulation 30, Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), this is to inform you that the Company has made further investment of 1,000 equity shares for an aggregate subscription amount of EUR 3,000,000 (Three Million Euros), at a nominal value of EUR 3,000 per share, in its wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., a company incorporated in Singapore to repay loans and other operational & financial obligations.

Tarsons Life Science Pte. Ltd is the 100% holding company for NERBE PLUS GMBH AND CO KG & NERBE R AND D GMBH based out in Germany.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (‘SEBI Circular’) are enclosed herewith as **Annexure-A**.

This is for your information and records.

Thanking you,

Yours Faithfully,
For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary & Compliance Officer
ICSI Membership No. A44836

Encl: As mentioned above

Annexure-A

The details required under Regulation 30 of the Listing Regulations read along with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November 2024:

Sr. No.	Particulars	Details
1.	Name of the Target Entity, details in brief such as size, turnover, etc.:	<p>Tarsons Life Science Pte. Ltd. ("Target Entity")</p> <p>Tarsons Life Science Pte. Ltd. is a wholly-owned subsidiary of Tarsons Products Limited ("the Company") incorporated in Singapore.</p> <p>The Turnover of the Target Entity for the F.Y. 2024-25 is Nil.</p>
2.	<p>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at "arm's length":</p>	<p>Tarsons Life Science Pte. Ltd. being a wholly-owned subsidiary is a related party of the Company.</p> <p>The transaction falls within the ambit of related party transaction and is at arm's length basis.</p> <p>None of the Company's promoter/promoter group/group companies have any interest in Target Entity.</p>
3.	Industry to which the entity being acquired belongs:	<p>Tarsons Life Science Pte. Ltd. is engaged in the Non-Operating Financial Holding Companies</p> <p>(The Target Entity is a Special Purpose Vehicle)</p>
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	<p>The additional capital infusion by the Company is to fund the needs of the target entity towards repayment of existing loans, meeting the general corporate purposes and other operational & financial expenses.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	<p>Necessary intimations for the additional investment in the Target Entity, which is a foreign subsidiary has been done with the Reserve Bank of India (RBI).</p>
6.	Indicative time period for completion of the acquisition:	Completed.

7.	Consideration - whether cash consideration or share swap or any other form and details of the same:	Cash consideration.						
8.	Cost of acquisition and/or the price at which the shares are acquired:	Total consideration for the acquisition of 1,000 equity shares is EUR 3,000,000 (Three Million Euros), at a nominal value of EUR 3,000 per share.						
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	No change in ownership/percentage of shareholding. Tarsons Life Science Pte. Ltd. will continue to be a wholly-owned subsidiary of Tarsons Products Limited.						
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	<p>Tarsons Life Science Pte. Ltd. is a 100% subsidiary based in Singapore of Tarsons Products Limited.</p> <p>Date of incorporation: November 10, 2023.</p> <p>Country in which the acquired entity has presence: Singapore</p> <p>The last two (2) years' turnover of Tarsons Life Science Pte. Ltd. is as under:</p> <table><tr><th>Financial Year</th><th>Amount in EUR</th></tr><tr><td>2024-25</td><td>Nil</td></tr><tr><td>2023-24</td><td>Nil</td></tr></table> <p>Any other significant information: Not applicable</p>	Financial Year	Amount in EUR	2024-25	Nil	2023-24	Nil
Financial Year	Amount in EUR							
2024-25	Nil							
2023-24	Nil							

For Tarsons Products Limited

Santosh Kumar Agarwal
CFO, Company Secretary & Compliance Officer
ICSI Membership No. A44836